Condition: Chronic Cholecystitis · Biliary Dyskinesia · Sponsor: Valenta Pharm JSC
The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| State Budgetary Institution of Healthcare of Moscow "City Polyclinic No. 2 of the Moscow Department of Healthcare" | Moscow, Russia | Recruiting |
| Unimed-C Jsc | Moscow, Russia | Recruiting |
| The State Budgetary Healthcare Institution of the Moscow Region "Moscow Regional Research Clinical Institute named after M.F. Vladimirsky" | Moscow, Russia | Recruiting |
| Limited Liability Company "ErSi Medical" | Novosibirsk, Russia | Recruiting |
| Federal State Budgetary Educational Institution of Higher Education "Academician E.A. Wagner Perm State Medical University" of the Ministry of Healthcare of the Russian Federation | Perm, Russia | Recruiting |
| St. Petersburg State Budgetary Healthcare Institution "City Polyclinic No. 117" | Saint Petersburg, Russia | Recruiting |
| Limited Liability Company "Research Center Eco-Safety" | Saint Petersburg, Russia | Recruiting |
| Limited Liability Company "Research Center Eco-Safety" | Saint Petersburg, Russia | Recruiting |
| Limited Liability Company "Clinic Zvezdnaya" | Saint Petersburg, Russia | Recruiting |
| State Healthcare Institution "Saratov City Clinical Hospital No. 5" | Saratov, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07595003